UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report - Seite 2
Governance impacts:
- Fortified our cybersecurity systems and protocols, implemented a Zero Trust framework.
- Updated our charters and policies to maintain strong governance practices, including shareholder proxy access.
Survey participation:
- In 2023, we completed our first CDP Climate survey and CDP Water survey, each for the year 2022.
- In 2022, a pilot study of 12% our Tier 1 suppliers completed sustainability surveys by our request, to help build our Scope 3 emissions inventory. In addition, we completed over one dozen sustainability surveys by request of our customers.
*SBTi: Science Based Targets initiative
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of
manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and
manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in
Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more
information, please visit www.repligen.com, and
follow us on LinkedIn.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that
statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,”
“seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results
to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to
update any forward-looking statements, except as required by law.
Lesen Sie auch
Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com